Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, January 19, 2017

Reflections on Neuroprotection Research and the Path Toward Clinical Success

By using this neutral name rather than an action causing name like the neuronal cascade of death, you are basically saying this is not really a problem for stroke survivors.  I do wonder if they have analyzed the reasons that 1000+ neuroprotective trials have failed as stated by  Dr. Michael.Tymianski@uhn.ca
Nothing here gives any sense of urgency because we don't know how much less than 1.9 million neurons are dying every minute. Any continuing death of neurons needs to be stopped. Neuroprotection gives NO sense of urgency. I bet they don't even know how long the neuronal cascade of death continues after the blockage or bleed is stopped.

http://link.springer.com/chapter/10.1007/978-3-319-45345-3_1
  • Paul A. Lapchak 
  • , Paul D. Boitano
$29.95 / €24.95 / £19.95 *
Buy eBook
$219.00 / €190.39 / £136.00*
* Final gross prices may vary according to local VAT.
Get Access

Abstract

Translational neuroprotection research is currently undergoing a rebirth, a much needed revival, in part due to the efficacy of both thrombolytic and endovascular procedures in subpopulations of ischemic stroke patients. Stroke is currently treated with the Food and Drug administration (FDA)-approved thrombolytic, tissue plasminogen activator (rt-PA), and can be treated with endovascular approaches using the MERCI stent retriever or the Solitaire FR stent retriever, with the application of thrombolytic (i.e., rt-PA or urokinase) prior to embolectomy for rt-PA eligible patients. Moreover, from retrospective analysis in rt-PA ineligible stroke patients, embolectomy alone has proven safe and beneficial if completed within 6 h.
Despite many decades of research into the identification and translational development of neuroprotective compounds, only few strategies have progressed into appropriately designed unbiased, randomized, placebo-controlled clinical trials. The FDA has still not been able to afford approval to a neuroprotectant to treat ischemic disease, primarily because of exaggerated overestimation of efficacy in rodent models that did not translate into efficacy in humans. During the process of developing neuroprotective compounds to treat ischemic diseases, stroke in particular, numerous problems have emerged including the absolute failure to translate preclinical animal efficacy into efficacy in stroke victims, and in some cases, both significant adverse events and unforeseen toxicities have hindered drug development and approval. This chapter describes successes and failures in the stroke neuroprotection research, provides a comprehensive tabulated assessment of select neuroprotectants that have been tested in clinical trials, and proposes recommendations and essential checklists to both guide and improve the quality of science being conducted in preclinical and translational laboratories worldwide. The ultimate goal is to reap the benefits of a worldwide concerted neuroprotection research effort to provide superior care to stroke victims.

No comments:

Post a Comment